A detailed history of Jump Financial, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 32,570 shares of ARVN stock, worth $846,168. This represents 0.02% of its overall portfolio holdings.

Number of Shares
32,570
Previous 31,762 2.54%
Holding current value
$846,168
Previous $845,000 5.09%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $19,117 - $26,445
808 Added 2.54%
32,570 $802,000
Q2 2024

Aug 14, 2024

BUY
$24.46 - $40.4 $776,898 - $1.28 Million
31,762 New
31,762 $845,000
Q4 2023

Oct 21, 2024

BUY
$14.19 - $42.33 $156,331 - $466,349
11,017 Added 104.03%
21,607 $889,000
Q4 2023

Feb 07, 2024

BUY
$14.19 - $42.33 $306,603 - $914,624
21,607 New
21,607 $889,000
Q2 2023

Oct 21, 2024

SELL
$21.73 - $31.43 $1.13 Million - $1.63 Million
-51,838 Reduced 83.04%
10,590 $262,000
Q2 2023

Aug 07, 2023

SELL
$21.73 - $31.43 $1.13 Million - $1.63 Million
-51,838 Reduced 83.04%
10,590 $262,000
Q1 2023

Oct 21, 2024

BUY
$26.15 - $37.26 $801,915 - $1.14 Million
30,666 Added 96.55%
62,428 $1.71 Million
Q1 2023

May 03, 2023

BUY
$26.15 - $37.26 $1.63 Million - $2.33 Million
62,428 New
62,428 $1.71 Million
Q2 2022

Aug 09, 2022

BUY
$36.01 - $74.24 $330,067 - $680,483
9,166 Added 214.31%
13,443 $566,000
Q1 2022

May 12, 2022

SELL
$60.27 - $81.57 $1.45 Million - $1.96 Million
-24,023 Reduced 84.89%
4,277 $288,000
Q4 2021

Feb 10, 2022

BUY
$65.85 - $96.21 $1.86 Million - $2.72 Million
28,300 New
28,300 $2.33 Million
Q1 2021

May 17, 2021

SELL
$58.19 - $91.37 $704,215 - $1.11 Million
-12,102 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$20.19 - $84.93 $244,339 - $1.03 Million
12,102 New
12,102 $1.03 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.38B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.